FibroGen shares slide after Duchenne muscular dystrophy treatment falls short in trial
Shares of FibroGen Inc. (FGEN) were down 5.6% premarket on Wednesday after the company announced disappointing results from a late-stage trial of pamrevlumab in non-ambulatory patients with Duchenne muscular dystrophy. The study did not meet the primary endpoint of upper-limb performance after 52 weeks, the company said, although pamrevlumab was generally safe and well tolerated. "While disappointed with these results, we look forward to sharing the data at a future medical conference to contribute towards the understanding of this devastating disease," FibroGen CEO Enrique Conterno said in a statement.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
June 07, 2023 08:09 ET (12:09 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
, 
, 
Copyright ©2023. All rights reserved.